Third Harmonic Bio Inc. Market Cap ($242.79 Million)
Market Cap & Net Worth: Third Harmonic Bio Inc. (THRD)
Third Harmonic Bio Inc. market cap. Third Harmonic Bio Inc. (NASDAQ:THRD) has a market capitalization of $242.79 Million ($242.79 Million) as of November 5, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #15595 globally and #3715 in its home market, demonstrating a 0.00% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Third Harmonic Bio Inc.'s stock price $5.38 by its total outstanding shares 45127800 (45.13 Million). Also see THRD cash flow metrics for how efficiently the company converts equity into cash flow.
Third Harmonic Bio Inc. Market Cap History (2022–2025)
Third Harmonic Bio Inc. market cap history from 2022 to 2025. Data shows change from $194.05 Million to $242.79 Million (-32.61% CAGR). Check Third Harmonic Bio Inc. stock quote for real-time trading data and today's change.
Index Memberships
Third Harmonic Bio Inc. is a constituent of 3 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
NASDAQ Health Care
IXHC
|
$2.62 Trillion | 0.01% | #416 of 976 |
|
NASDAQ Composite
IXIC
|
$40.12 Trillion | 0.00% | #1522 of 3165 |
|
NASDAQ Biotechnology
NBI
|
$1.84 Trillion | 0.01% | #214 of 263 |
Weight: Third Harmonic Bio Inc.'s market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
Third Harmonic Bio Inc. Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Third Harmonic Bio Inc.'s valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Explore THRD year-over-year net asset growth to track how rapidly the company is growing its equity base year over year.
Latest Price to Sales (P/S) Ratio
No P/S ratio data available
Latest Price to Earnings (P/E) Ratio
No P/E ratio data available
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| No financial ratio data available | |||||
Competitor Companies of THRD by Market Capitalization
Companies near Third Harmonic Bio Inc. in the global market cap rankings as of November 5, 2026. Also see THRD current and non-current assets for a full breakdown of the balance sheet.
Key companies related to Third Harmonic Bio Inc. by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #181 globally with a market cap of $130.90 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #373 globally with a market cap of $76.14 Billion USD.
- CSL Ltd (AU:CSL): Ranked #415 globally with a market cap of $67.74 Billion USD ( AU$95.74 Billion AUD).
- Moderna Inc (NASDAQ:MRNA): Ranked #503 globally with a market cap of $54.14 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #181 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $130.90 Billion | $549.04 |
| #373 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $76.14 Billion | $930.67 |
| #415 | CSL Ltd | AU:CSL | $67.74 Billion | AU$197.34 |
| #503 | Moderna Inc | NASDAQ:MRNA | $54.14 Billion | $258.38 |
Market Capitalization of Third Harmonic Bio Inc. (2022–2025)
Market capitalization of Third Harmonic Bio Inc. from 2022 to today. Between 2022 and today, Third Harmonic Bio Inc.'s market cap moved from $194.05 Million to $ 242.79 Million, with a yearly change of -32.61%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2025 | $242.79 Million | -47.72% |
| 2024 | $464.37 Million | -6.20% |
| 2023 | $495.05 Million | +155.12% |
| 2022 | $194.05 Million | -- |
End of Day Market Cap According to Different Sources
On Aug 12th, 2026 the market cap of Third Harmonic Bio Inc. was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $242.79 Million USD |
| MoneyControl | $242.79 Million USD |
| MarketWatch | $242.79 Million USD |
| marketcap.company | $242.79 Million USD |
| Reuters | $242.79 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Third Harmonic Bio Inc.
Third Harmonic Bio, Inc., a biopharmaceutical company, focuses on the development of the medicine for the treatment of dermal, respiratory, and gastrointestinal inflammatory diseases. The company develops oral small-molecule inhibitors of KIT, a cell surface receptor that serves as the master regulator of mast cell function and survival. It also develops THB335, an oral small molecule KIT inhibit… Read more